Authors
Julia Rüdebusch, Alexander Benkner, Neetika Nath, Lina Fleuch, Lars Kaderali, Karina Grube, Karin Klingel, Gertrud Eckstein, Thomas Meitinger, Jens Fielitz, Stephan B Felix
Publication date
2022/6
Source
British journal of pharmacology
Volume
179
Issue
11
Pages
2430-2442
Description
Background and Purpose
Heart failure is associated with an impaired NO–soluble guanylyl cyclase (sGC)–cGMP pathway and its augmentation is thought to be beneficial for its therapy. We hypothesized that stimulation of sGC by the sGC stimulator riociguat prevents pathological cardiac remodelling and heart failure in response to chronic pressure overload.
Experimental Approach
Transverse aortic constriction or sham surgery was performed in C57BL/6N mice. After 3 weeks of transverse aortic constriction when heart failure was established, animals receive either riociguat or its vehicle for 5 additional weeks. Cardiac function was evaluated weekly by echocardiography. Eight weeks after surgery, histological analyses were performed to evaluate remodelling and the transcriptome of the left ventricles (LVs) was analysed by RNA sequencing. Cell culture experiments were used for mechanistically studies.
Key …
Total citations
20212022202320247569
Scholar articles